← Back to Search

Topical Analgesic

Capsaicin for CHS

Phase 4
Waitlist Available
Led By Angela Holian, PharmD
Research Sponsored by University of Virginia
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
At least 18 years old
Diagnosis of cannabinoid hyperemesis syndrome
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30 days (outpatient phone call)
Awards & highlights

Study Summary

This trial will test if capsaicin cream can help people with a condition that causes them to vomit a lot.

Eligible Conditions
  • CHS
  • Cannabinoid Hyperemesis Syndrome

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30 days (outpatient phone call)
This trial's timeline: 3 weeks for screening, Varies for treatment, and 30 days (outpatient phone call) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Time to resolution of symptoms
Secondary outcome measures
Clinical improvement in pain score
Other outcome measures
Symptom improvement at thirty days

Side effects data

From 2018 Phase 4 trial • 80 Patients • NCT02288156
31%
nasopharyngitis
19%
Nasal congestion
13%
Cough
13%
Rhinorrhoea
6%
Pyrexia
6%
Cystitis
6%
Rhinitis
6%
Influenza
6%
Sneezing
6%
Laryngitis
6%
pain in extremity
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo
0,01mM
0,1mM
0.001mM

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: CapsaicinExperimental Treatment1 Intervention
capsaicin 0.075% cream applied once topically
Group II: PlaceboActive Control1 Intervention
placebo cream applied once topically
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Capsaicin
FDA approved

Find a Location

Who is running the clinical trial?

University of VirginiaLead Sponsor
748 Previous Clinical Trials
1,235,953 Total Patients Enrolled
Angela Holian, PharmDPrincipal Investigator - University of Virginia
University of Virginia

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many individuals are participating in this therapeutic trial?

"Affirmative. According to the details hosted on clinicaltrials.gov, this trial began recruiting on December 1st 2020 and is still actively looking for participants. The study needs 50 individuals from one location to complete it."

Answered by AI

Is recruitment still ongoing for this research endeavor?

"Affirmative. According to records available on clinicaltrials.gov, the trial was initially posted on December 1st 2020 and is currently open for enrollment. This study needs 50 participants from a single location."

Answered by AI

What medical afflictions does Capsaicin commonly address?

"Capsaicin has been identified as a potential treatment for collagen diseases, acute nonspecific tenosynovitis, and musculoskeletal pain."

Answered by AI

What risks do users face when exposed to Capsaicin?

"Capsaicin has been granted approval, so it is given a score of 3. This assessment was made by the Power team on their 1 to 3 scale."

Answered by AI
~12 spots leftby Mar 2025